Physician profile
Taylor E Cain
NPI 1679037147
$1,047.91
in general payments reported to CMS, 2019-2025
11 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $198 · 2023: $141 · 2024: $180 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.51 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $356.09 | 2023-2025 | Carvykti, Talvey, Tecvayli |
| Janssen Biotech, INC. | $136.85 | 2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $126.21 | 2024 | |
| Adc Therapeutics America, INC. | $99.39 | 2022 | |
| Incyte Corporation | $99.00 | 2022 | |
| Amgen INC. | $91.72 | 2021 | |
| Kite Pharma, INC. | $32.61 | 2025 | Yescarta |
| Karyopharm Therapeutics INC. | $28.92 | 2025 | Xpovio |
| Legend Biotech USA INC. | $27.83 | 2025 | Carvykti |
| Morphosys, US INC. | $24.75 | 2021 | |
| Celgene Corporation | $24.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.